Hilbert Blank
Papers
1
Total Citations
54
H-Index
1
About
Hilbert Blank is a leading figure in radiation oncology, with a primary focus on stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC). His most influential work, the 2017 "Planning benchmark study for SBRT of early stage NSCLC," has garnered 54 citations and serves as a critical reference for standardizing treatment planning across institutions. This study systematically evaluated dosimetric parameters and target volume delineation, establishing best practices that have directly improved the consistency and safety of SBRT delivery. Blank’s contributions have helped refine dose constraints for organs at risk, reducing toxicity while maintaining high tumor control rates. His research bridges the gap between clinical trial protocols and real-world implementation, making him a key resource for radiation oncologists and medical physicists. Beyond this benchmark study, Blank has actively participated in multi-center collaborations, advancing the evidence base for hypofractionated regimens. His work remains essential reading for trainees and practitioners seeking to optimize SBRT for lung cancer, demonstrating a lasting impact on both clinical practice and patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1Planning benchmark study for SBRT of early stage NSCLC54 citations · 2017